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1. INTRODUCTION 
Diabetes is a serious health condition and is a major contributor to heart disease, kidney 
disease, stroke, vascular/blood vessel disease, and vision loss. Prevalence of diabetes 
increased dramatically from 1990 through 2009 (leveling off since then), with nearly 26 
million Americans currently living with this condition. Given health complications associated 
with diabetes and its increasing prevalence, the disease imposes a large and growing 
economic burden on the health care system and society. Besides the individuals with 
diabetes themselves, other parties are also affected by the financial burden of diabetes, 
including private insurers, state and federal governments, and employers. 
Preventing type 2 diabetes and diabetes complications could result in improved health and 
reduced downstream health care costs. The Centers for Disease Control and Prevention 
(CDC) works with state health departments and other stakeholders interested in diabetes 
prevention and control, including insurers, employers, and community-based organizations, 
to reduce the health and economic burden associated with diabetes by preventing diabetes 
and improving diabetes care. These organizations have an emerging need for information on 
the health and economic burden of diabetes at the state and local levels and the impact of 
investments in type 2 diabetes prevention efforts.  
Toolkits can provide a fast, convenient, and reliable way to generate state-level estimates of 
the health and economic burden of diabetes in adults and assess the impact of interventions 
targeting prevention and delay of type 2 diabetes. CDC has contracted with RTI 
International to develop two online toolkits: one to calculate and report the state-level 
health and economic burden of diabetes (Diabetes State Burden Toolkit, or the Burden 
Toolkit, for short) and another to estimate the potential health and economic impacts of 
implementing evidence-based type 2 diabetes prevention interventions (Diabetes Prevention 
Impact Toolkit, or the Impact Toolkit, for short) for states, employers, and health insurers. 
This technical report describes the data and methods used to generate estimates presented 
in the Burden Toolkit. 
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2. DATA AND METHODS 
The Burden Toolkit consists of three sections: (1) diabetes health burden, (2) diabetes 
economic burden, and (3) diabetes mortality. Estimates reported in the Burden Toolkit are 
for adults only and exclude children younger than age 18. Estimates are reported for type 1 
and type 2 diabetes combined because of data limitations.  
2.1 Diabetes Health Burden 
This section of the Burden Toolkit reports the health burden of diabetes in each state and 
nationally and reports statistics on diabetes prevalence, diabetes incidence, and diabetes-
associated conditions. Reporting of diabetes-associated conditions is based on self-reported 
data, hospitalization data, and Medicare data. 
The following annual estimates are reported in the health burden section of the Burden 
Toolkit at the state level and nationally: 
1. Diabetes prevalence: 
a. Age-adjusted prevalence of diabetes in total and by sex 
b. Estimated number of people with diabetes in total and by age group/sex 
c. Prevalence of diabetes in total and by age group/sex (with 95% confidence 
intervals [CI]) 
2. Diabetes incidence: 
a. Crude rate of new cases of diagnosed diabetes per 1,000 (with 95% CI) 
b. Age-adjusted rate of new cases of diagnosed diabetes per 1,000 (with 95% CI) 
c. Number of new cases of diagnosed diabetes (with 95% CI) 
3. Associated conditions: 
a. Self-reported data: 
i. Age-adjusted prevalence of conditions among adults with diabetes, in total 
and by sex 
ii. Number of adults with conditions and diabetes, in total and by age 
iii. Prevalence of conditions among adults with diabetes, in total and by age (with 
95% CI) 
iv. Number of condition cases attributable to diabetes, in total and by age 
b. Hospitalization data: 
i. Age-adjusted rate of hospitalizations with conditions among adults with 
diabetes, in total and by sex 
ii. Number of hospitalizations with conditions among adults with diabetes by age 
group/sex 
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iii. Rate of hospitalizations with conditions among adults with diabetes by age 
group/sex (with 95% CI) 
iv. Number of diabetes-attributable hospitalizations with conditions 
c. Medicare data 
i. Age-adjusted prevalence of conditions among Medicare beneficiaries with 
diabetes by age group/sex 
ii. Number of people with conditions among Medicare beneficiaries with diabetes 
by age group/sex 
iii. Prevalence of conditions among Medicare beneficiaries with diabetes by age 
group/sex (with 95% CI) 
iv. Number of conditions attributable to diabetes 
Each component of the health burden section is described in detail in the following 
subsections. 
2.1.1 Diabetes Prevalence 
We used the 2013 Behavioral Risk Factor Surveillance System (BRFSS) data and followed 
approaches used by CDC’s United States Diabetes Surveillance System (available at 
http://gis.cdc.gov/grasp/diabetes/DiabetesAtlas.html) to estimate prevalence of diabetes. 
BRFSS is a state-based, cross-sectional telephone interview survey conducted by CDC and 
state health departments annually (CDC, 2014). The survey represents the civilian 
noninstitutionalized adult population in each of the 50 states and the District of Columbia 
(DC). BRFSS is used to collect prevalence data regarding risk behaviors and preventive 
health practices among U.S. adults. We excluded respondents with missing age or missing 
diabetes status from the analysis and, using BRFSS sample weights, calculated the 
percentage of adults who answered “yes” to the question, “Has a doctor, nurse, or other 
health professional ever told you that you have diabetes?” 
This diabetes prevalence was calculated by age group (18–44, 45–64, 65–74, and 75 or 
older) and sex. We used the rule of sample size greater than 50 and relative standard error 
(RSE) of less than 30% to evaluate whether each age group/sex cell provided reliable 
estimates. The data were not reliable by sex in the 18 to 44 age category in DC and eight 
states: Alaska, Arizona, Delaware, Idaho, Nevada, New Hampshire, Vermont, and 
Wisconsin. For these locations, we collapsed the data across men and women and reported 
one estimate for the 18 to 44 age group (without the sex stratification). 
We multiplied the percentage of people with diabetes in each age group/sex cell by the 
weighted number of total respondents in each age group/sex cell to calculate the total 
number of adults with diabetes in each age group/sex cell. We age-adjusted total and by 
sex estimates of prevalence of diabetes and conditions to the 2000 U.S. standard population 
following methodology described by Klein et al. (2001). 
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2.1.2 Diabetes Incidence 
For diabetes incidence, we used crude and age-adjusted rates of newly diagnosed cases of 
diabetes for 2013 downloaded from the CDC Web site 
(http://gis.cdc.gov/grasp/diabetes/DiabetesAtlas.html). These estimates were derived from 
the BRFSS.  Self-reported diagnosed diabetes was defined by using the survey question, 
“Has a doctor, nurse, or other health professional ever told you that you have diabetes?” 
The age at which each person was diagnosed with diabetes was defined by using the survey 
question, “How old were you when you were told you have diabetes?” We calculated the 
number of years each person had been diagnosed with diabetes by subtracting the age at 
which they were diagnosed from their current age. Adults who had a value of zero were 
identified as having been diagnosed with diabetes within the last year. In addition, half of 
the adults who had a value of one were classified as having been diagnosed with diabetes 
within the last year. To calculate incidence, the numerator was the weighted number of 
adults who were diagnosed with diabetes within the last year, and the denominator was the 
weighted estimate of the adult population, excluding adults who had been diagnosed with 
diabetes for more than 1 year and adults who answered “refused,” “don’t know,” or had 
missing values on the diabetes status question. Three-year averages were used to improve 
the precision of the annual estimates. States with less than 2 years of data were excluded 
from the analysis (18 states and DC). States for which incidence rates or numbers were not 
estimated for 2013 are indicated with “No Data” in the Burden Toolkit. 
2.1.3 Diabetes-Associated Conditions 
The Burden Toolkit reports statistics on diabetes-associated conditions from three types of 
data sources: (1) self-reported conditions from BRFSS, (2) hospitalization events from the 
Healthcare Cost and Utilization Project (HCUP) State Inpatient Databases (SID), and 
(3) claims from the Medicare data. BRFSS self-reported conditions are hypertension, high 
cholesterol, severe vision impairment or blindness, mobility limitations, limitations in 
instrumental activities of daily living, and coronary heart disease (CHD). Estimates from 
BRFSS represent self-reported lifetime prevalence and are mostly defined using “have you 
ever been told” questions. Hospitalization events from SID are congestive heart failure 
(CHF), stroke, myocardial infarction (MI), lower extremity amputations (LEAs), 
hyperosmolar hyperglycemic nonketotic syndrome (HHNS), diabetic ketoacidosis (DKA), and 
hypoglycemia. Results from SID represent events for which individuals were hospitalized 
within a given year. Claims from the Medicare data are reported for CHD, CHF, chronic 
kidney disease (CKD), and peripheral vascular disease. Estimates from Medicare data 
represent treated events among Medicare beneficiaries. Because of differences in definitions 
of conditions from different data sources, estimates of the same diseases (e.g., CHD) across 
the data sources are not comparable. For each condition, the Burden Toolkit reports the rate 
of the condition among people with diabetes and the number of cases attributable to 
diabetes. 
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2.1.2.1 Self-reported Data 
We used 2013 BRFSS data to estimate self-reported diabetes-associated conditions. A list of 
these conditions and questions used to define each of them are presented in Table 2-1. 
Although BRFSS also includes limitations in activities of daily living, we did not report this 
condition in the Burden Toolkit due to data unreliability. 
Table 2-1. Definitions of Self-Reported Diabetes-Associated Conditions, 2013 
Behavioral Risk Factor Surveillance System 
Condition Definition 
Hypertension Have you ever been told by a doctor, nurse, or other 
health professional that you have high blood pressure? (If 
“Yes” and respondent is female, ask “Was this only when 
you were pregnant?”) 
High cholesterol Have you ever been told by a doctor, nurse or other 
health professional that your blood cholesterol is high? 
Severe vision impairment or blindness  Are you blind or do you have serious difficulty seeing, 
even when wearing glasses? 
Mobility limitations Do you have serious difficulty walking or climbing stairs? 
Limitations in instrumental activities of 
daily living 
Because of a physical, mental, or emotional condition, do 
you have difficulty doing errands alone such as visiting a 
doctor’s office or shopping? 
Coronary heart disease Has a doctor, nurse, or other health professional ever told 
you that you had angina or coronary heart disease? 
OR 
Has a doctor, nurse, or other health professional ever told 
you that you had a heart attack, also called a myocardial 
infarction? 
 
We estimated the prevalence of each self-reported condition among people with diabetes by 
calculating the percentage of people with diabetes who responded “yes” to the 
corresponding condition question using BRFSS sample weights. We excluded respondents 
with missing age, missing diabetes status, and/or a missing response to the conditions 
question. Additionally, we excluded women reporting diabetes or hypertension during 
pregnancy only (gestational diabetes and gestational hypertension). We report prevalence 
estimates by age categories (18–44, 45–64, 65–74, and 75 or older). As with diabetes 
prevalence, we used the data reliability criteria of sample size less than 50 or RSE greater 
than 30% and aggregated age categories that did not meet both of the criteria. The level of 
aggregation varied across conditions and across states. For example, for hypertension, we 
report prevalence for all four age categories in 39 states; in the remaining 11 states and 
DC, we had to aggregate the two youngest age categories together and report prevalence of 
hypertension for three age groups: 18–64, 65–74, and 75 or older. We calculated the 
number of people with each condition and diabetes by age by multiplying prevalence of the 
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condition among people with diabetes in each age category by the weighted number of 
people with diabetes from BRFSS in each age category. 
We estimated the number of condition cases attributable to diabetes using an attributable 
fraction (AF) approach. In the epidemiologic literature, AFs are used to estimate the 
proportion of disease risk in a population that can be attributed to a risk factor or set of risk 
factors (Flegal, Graubard, & Williamson, 2004; Rockhill, Newman, & Weinberg, 1998). 
Because the prevalence of diabetes and its attributable conditions increase with age, the 
AFs should be estimated separately by age group. Rockhill, Newman, and Weinberg (1998) 
and Flegal, Graubard, and Williamson (2004) explain that when confounding factors and/or 
effect modifications are present, the correct formula for calculating the diabetes AF for 
disease j is shown in Equation 1: 
 





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
 −
=
j
j
jj RR
RR
pdAF
1
 (1) 
where pdj is the adjusted prevalence of diabetes in the subsample with the condition j, and 
RRj is the adjusted relative risk (RR) of condition j in the diabetes subsample relative to the 
non-diabetes sample. For each age group, we predicted the probability of having diabetes 
among individuals with the condition (pdj) using a logit command in Stata and controlling 
for age (in years), sex, and race/ethnicity (black, Hispanic, other race [including missing 
race], and white [variable omitted from the regression model]). The model was weighted 
using BRFSS sample weights to account for the survey design of the data. 
For each age group, we also estimated the RR of each condition, which is the ratio of the 
condition prevalence among people with diabetes to the condition prevalence among people 
without diabetes (see Equation 2). We estimated the RR using a generalized linear model 
(GLM) with a Poisson family and a log link and controlling for age, sex, and race/ethnicity. 
The GLM regressions were also weighted using BRFSS sample weights. 
 
Diabetes without People Among Prevalence onComplicati
Diabetes with People Among Prevalence onComplicati
=RR  (2) 
Our standard specification included four race/ethnicity groups: black, Hispanic, other 
(including missing race), and white (omitted category). However, we identified quasi-
complete separation (QCS) in several age/condition/state stratifications, which occurs when 
all individuals in one race/ethnicity group have the outcome variable as all zeroes or all ones 
(e.g., every Hispanic aged 18 to 44 who has CHD also has diabetes given their age [in 
years]). When QCS occurred, we aggregated race/ethnicity into three groups: black, other 
(including missing race and Hispanics), and white (omitted category). If QCS was still 
present in the more aggregated model, we used results from a model without race/ 
ethnicity controls. 
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For each age/condition/state stratification, we used the same model specification for 
predicting probability of diabetes as for estimating the RR. For example, if we used results 
from a logit model without race/ethnicity controls to predict the probability of diabetes 
among adults aged 18 to 44 with CHD in one state, then we used the same specification 
(i.e., without race controls) in the GLM regression predicting the RR in that state. 
We estimated the number of cases of each condition attributable to diabetes by multiplying 
the number of cases of each condition by the diabetes AF (see Equation 3): 
 
jj
j
AFcondition with people ofNumber 
diabetes to leattributab cases condition ofNumber 
∗
=
 (3) 
Note that in the states where prevalence of the diabetes-associated conditions was 
estimated for three age groups and in total (instead of four age groups and in total), the 
number of attributable cases is also reported for three age groups and in total. At the 
national level, estimates are reported for four age groups and in total; thus, the national 
number of diabetes-attributable cases summed across four age groups does not add up to 
the reported total (because in some states the data are not available by four age groups). 
For example, in Alaska, the number of diabetes-attributable cases of high blood pressure is 
reported for age groups 18 to 64, 65 to 74, 75 or older, and in total (18 or older). At the 
national level, the number of cases reported for the 18 to 44 or 45 to 64 age groups does 
not include the estimates from Alaska, but they are included in the total count for ages 18 
or older. As a result, the number of diabetes-attributable cases by age groups at the 
national level may be underestimated. We report the number of cases attributable to 
diabetes in thousands. In the Burden Toolkit, we do not report the number of condition 
cases attributable to diabetes for age categories where the p-value for the RR was >0.10 
(the cells are left blank, and a note indicates that the data were unreliable). 
2.1.2.2 Hospitalization Data 
We used HCUP SID data sponsored by the Agency for Healthcare Research and Quality 
(AHRQ) to estimate hospitalizations with diabetes-associated conditions (AHRQ, April 2016). 
The SID captures hospital inpatient stays in a given state and contains clinical and resource-
use information that is included in a typical discharge abstract (AHRQ, June 2016). We 
analyzed publicly available data for 28 states and directly obtained estimates for 18 states 
and DC from AHRQ HCUP through active intramural collaboration. The most recently 
available years of data for SID vary across the states and are listed in Table 2-2. Three 
states (Alabama, Delaware, and Idaho) do not participate in the HCUP SID; thus, we were 
not able to report hospitalization data for them. New Hampshire’s latest year of available 
data was 2009, and thus this state was also excluded from our analyses. 
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Table 2-2. Most Recent Year of Data from the State Inpatient Databases 
State Year of Data from SID 
Alaska 2012 
Arizona 2013 
Arkansas 2012 
California 2011 
Colorado 2013 
Connecticut 2014 
District of Columbia 2014 
Florida 2013 
Georgia 2014 
Hawaii 2012 
Illinois 2013 
Indiana 2014 
Iowa 2013 
Kansas 2014 
Kentucky 2013 
Louisiana 2014 
Maine 2011 
Maryland 2012 
Massachusetts 2012 
Michigan 2012 
Minnesota 2014 
Mississippi 2011 
Missouri 2013 
Montana 2014 
Nebraska 2013 
Nevada 2012 
New Jersey 2013 
New Mexico 2012 
New York 2012 
North Carolina 2012 
North Dakota 2014 
Ohio 2013 
Oklahoma 2014 
Oregon 2013 
Pennsylvania 2014 
(continued) 
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Table 2-2. Most Recent Year of Data from the State Inpatient Databases 
(continued) 
State Year of Data from SID 
Rhode Island 2012 
South Carolina 2013 
South Dakota 2012 
Tennessee 2014 
Texas 2014 
Utah 2011 
Vermont 2013 
Virginia 2014 
Washington 2013 
West Virginia 2012 
Wisconsin 2013 
Wyoming 2014 
Note: Three states (Alabama, Delaware, and Idaho) do not participate in the Healthcare Cost and 
Utilization Project State Inpatient Databases; thus, we were not able to report hospitalization data 
for them. New Hampshire’s latest year of available data was 2009, and thus this state was also 
excluded from our analyses. 
In SID, we identified persons with diabetes based on ICD-9 code 250 listed in any order 
diagnosis. Diabetes-associated conditions were defined using a primary (i.e., first-order) 
diagnosis code (with the exception of LEAs). Conditions, for which we report hospitalization 
data, and the ICD-9 codes used to identify each of them are listed in Table 2-3. 
Table 2-3. Definitions of Hospitalizations with Diabetes-Associated Conditions, 
State Inpatient Databases 
Condition ICD-9 Code 
Congestive heart failure 428 
Stroke 430–434, 436–438 
Myocardial infarction 410 
Lower extremity amputation 84.10–84.19a (but exclude 895–897) 
Hyperosmolar hyperglycemic 
nonketotic syndrome 
250.2 
Diabetic ketoacidosis 250.1 
Hypoglycemia 251.0, 251.1, 251.2, 962.3, 250.8 (250.8 is only counted if it is 
without 259.8, 272.7, 681–682, 686.9, 707.1, 707.8, 707.9, 
709.3, 730.0, 730.1, 730.2, 731.8) 
a Based on procedure codes. 
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We calculated hospitalization rate with each condition per 1,000 adults with diabetes by age 
group/sex using Equation 4: 
 000,1
Diabetes with People ofNumber 
 
Diabetes and Condition with
edHospitaliz People ofNumber 
Diabetes with Adults 1,000Per
 Rate ationHospitaliz Condition
×=  (4) 
The number of people hospitalized with the condition and diabetes was obtained from the 
SID, and the number of people with diabetes was obtained from the 2013 BRFSS data. 
For CHF, MI, and LEAs, we calculated the number of hospitalizations with each condition 
attributable to diabetes using the AF approach presented in Formula 1 where pdj is the 
adjusted prevalence of diabetes among those hospitalized with condition j, and RRj is the 
adjusted RR of hospitalization with condition j among those hospitalized with and without 
diabetes. For each age/sex group, we used a logit model to predict the probability of having 
diabetes among people with the condition controlling for age (in years) and race/ethnicity. 
In three states, age was coded in 5-year intervals. In those cases, we recoded the age 
variable as continuous and set it to the middle point of the 5-year interval. We followed the 
same approach for dealing with QCS as described for the BRFSS conditions. We then used a 
GLM with a Poisson family and a log link to estimate RR of each condition. 
When reporting the number of estimated cases of diabetes-attributable hospitalizations in 
the Burden Toolkit, we rounded the estimate to the nearest 10. We used the following rules 
to replace unreliable or insufficient results: 
1. Replace the number of hospitalizations with the condition and diabetes with 11 if the 
original number is <11 (these replacements occurred in 152 out of 2,444 
state/condition/age/sex categories). 
2. Replace the number of diabetes-attributable hospitalizations with zero if the number 
of hospitalizations with the condition and diabetes is <11 or the p-value for the RR is 
>0.10 (these replacements occurred in 116 out of 1,128 state/condition/age/sex 
categories). 
We did not report the number of stroke hospitalizations attributable to diabetes in any of 
the states because of high frequency of unreliable data or insufficient sample size. We 
assumed that all hospitalizations with HHNS, DKA, or hypoglycemia were attributed to 
diabetes. 
We calculated the number of hospitalizations with conditions and diabetes and the number 
of diabetes-attributable hospitalizations with conditions at the national level by applying the 
hospitalization rates and AFs aggregated across the 46 states, for which we had SID results, 
and DC to the total population counts across all states. Readers should also note that, 
although the national estimates are reported at the annual level, the years of data vary 
across states (see Table 2-2). 
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2.1.2.3 Medicare Data 
We used data from the Centers for Medicare & Medicaid Services (CMS) 2013 Master 
Beneficiary Summary File (MBSF) to estimate diabetes-associated conditions among 
Medicare beneficiaries with diabetes. We merged data from the MBSF Base Segment, the 
Chronic Conditions Warehouse (CCW) Segment, the Other Chronic or Potentially Disabling 
Conditions Segment, and the Cost and Utilization Segment (ResDAC, 2016). We restricted 
our analysis to beneficiaries aged 65 or older; we also removed individuals aged 90 or older 
with no health care use in the past 12 months to eliminate possible deceased cases. 
Furthermore, we restricted the analysis sample to beneficiaries with full fee-for-service 
(FFS) coverage during a 2-year reference period (with Part A and Part B coverage and 
without health management organization coverage). 
The following diabetes-associated conditions were estimated from the Medicare data: CHD, 
CHF, CKD, and peripheral vascular disease. We used already-defined variables from the 
CCW Chronic Conditions segment and the Other Chronic or Potentially Disabling Conditions 
segment of the MSBF to identify beneficiaries with diabetes and diabetes-associated 
conditions. In these data sources, the variables indicate medical treatment for a condition 
and are defined using algorithms based on inpatient and outpatient claims (Chronic 
Conditions Data Warehouse, 2016). For all of the conditions used in our analysis, CMS uses 
a reference period of 2 years to identify presence of a condition. We used variables called 
the end-of-year indicators to identify beneficiaries with the conditions, which means that the 
algorithm criteria were applied using December 31, 2013, as the end of the reference 
period. To restrict the sample to fully covered FFS beneficiaries, we excluded beneficiaries 
with the diabetes end-of-year flag equal to 0 (neither claims, no coverage met) or 1 (claims 
met, coverage not met). Beneficiaries with the end-of-year flag indicators equal to 3 (claims 
and coverage met) were defined as having the condition. 
For each state, we calculated the prevalence of conditions among beneficiaries with diabetes 
as the percentage of beneficiaries with diabetes who also have the condition. Estimates 
were generated by age group/sex with two age groups (65 to 74 and 75 or older). 
For each state, we calculated the number of condition cases attributable to diabetes using 
the AF approach presented in Equation 1 where pdj is the adjusted prevalence of diabetes 
among those with condition j, and RRj is the adjusted RR of condition j among those with 
and without diabetes. For each age/sex group, we used a logit model to predict the 
probability of having diabetes among people with the condition controlling for age (in years) 
and race/ethnicity. We used the same approach to address the QCS as with the BRFSS data. 
We then used a GLM with a Poisson family and a log link to estimate the RR of each 
condition. P-values for all RRs that we estimated were <0.05. 
In the MSBF, CCW indicators are not available for beneficiaries enrolled in managed care, 
thus our estimates were based on a sample restricted to the fully covered FFS beneficiaries. 
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We extrapolated the number of cases with condition and diabetes and the number of 
diabetes-attributable cases to the entire Medicare population in the state using a state/age 
group/sex-specific multiplier. For each state/age group/sex stratification, this multiplier was 
calculated as the number of total Medicare beneficiaries divided by the number of fully 
covered FFS beneficiaries. 
When reporting the number of estimated cases of diabetes-attributable conditions in the 
Burden Toolkit, we rounded the estimate to the nearest 10. 
2.2 Diabetes Economic Burden 
This section of the Burden Toolkit reports the economic burden of diabetes in each state, 
which consists of medical (direct) and indirect costs of diabetes. All costs are reported in 
2013 dollars. 
The following annual estimates are reported in the economic burden section of the Burden 
Toolkit at the state level and nationally: 
1. Total costs attributable to diabetes, in total and by age group/sex: 
a. Direct costs 
b. Indirect costs 
c. Total costs, in total and per person with diabetes 
2. Medical costs attributable to diabetes: 
a. All Payers, in total and by age group/sex: 
i. Per person medical costs 
ii. Total medical costs 
b. By Payer: 
i. Per person and total medical costs paid by Medicare 
ii. Per person and total medical costs paid by Medicaid 
iii. Per person and total medical costs paid by other payers 
iv. Per person and total medical costs paid by all payers 
c. By Payer, by age group/sex: 
i. Total medical costs paid by Medicare 
ii. Total medical costs paid by Medicaid 
iii. Total medical costs paid by other payers 
iv. Total medical costs paid by all payers 
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3. Indirect costs attributable to diabetes: 
a. Total: 
i. Morbidity costs: total and per person with diabetes 
ii. Work absenteeism costs: total and per person with diabetes 
iii. Presenteeism costs: total and per person with diabetes 
iv. Household productivity losses: total and per person with diabetes 
v. Inability to work costs: total and per person with diabetes 
vi. Mortality costs: total and per person with diabetes 
vii. Total indirect costs: total and per person with diabetes 
b. Work absenteeism, in total and by age group/sex: 
i. Number of work days lost per employed person with diabetes 
ii. Cost per employed person with diabetes 
iii. Cost per person with diabetes 
iv. Total cost 
c. Presenteeism, in total and by age group/sex: 
i. Number of work days lost per employed person with diabetes 
ii. Cost per employed person with diabetes 
iii. Cost per person with diabetes 
iv. Total cost 
d. Household productivity losses, in total and by age group/sex: 
i. Number of days lost per person with diabetes 
ii. Cost per person with diabetes 
iii. Total cost 
e. Inability to work, in total and by age group/sex: 
i. Number of persons unable to work because of diabetes 
ii. Cost per person with diabetes unable to work 
iii. Cost per person with diabetes 
iv. Total cost 
f. Mortality, in total and by age group/sex: 
i. Number of deaths attributable to diabetes 
ii. Labor costs 
iii. Household productivity costs 
iv. Total costs 
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4. Costs by perspective, in total and by age group/sex: 
a. State Medicaid Program: 
i. Estimated per person costs incurred by the state Medicaid program 
ii. Estimated total costs incurred by state Medicaid program 
b. Private Insurers: 
i. Estimated per person costs incurred by private insurers 
ii. Estimated total costs incurred by private insurers 
c. Employers: 
i. Estimated per person costs incurred by employers 
ii. Estimated total costs incurred by employers 
2.2.1 Total Costs of Diabetes 
This section of the Burden Toolkit reports the total costs attributable to diabetes in each 
state, which includes diabetes-attributable medical costs and diabetes-attributable indirect 
costs. Medical costs are estimated as the portion of state health expenditures from National 
Health Expenditure Accounts (NHEA) attributable to diabetes (including nursing home costs 
for institutionalized residents), as described in detail in Section 2.2.2. Indirect costs reflect 
the labor and household productivity losses that arise when diabetes causes missed 
workdays (i.e., absenteeism costs), on-the-job productivity losses (i.e., presenteeism 
costs), household productivity losses, disability that prevents people from working, or early 
mortality. Methods for estimating indirect costs are described in Section 2.2.3. In the 
Burden Toolkit, total costs are reported in total and by age and sex groups. 
2.2.2 Medical Cost of Diabetes 
This section of the Burden Toolkit reports diabetes-attributable direct medical costs, which 
are presented as costs for all payers, costs by payer, and costs by payer, age group, and 
sex. We used an AF approach to estimate state health expenditures attributable to diabetes. 
National and state health expenditures are regularly compiled by CMS (CMS, 2014). To 
implement this approach, we first estimated the fraction of medical spending for various 
services, such as ambulatory services, prescription drugs, hospital care, and other services, 
attributable to diabetes. The general formula used for AF is presented in Equation 5: 
 
( )
( )11
1
−×+
−×
=
RRpd
RRpd
AF  (5) 
where AF represents the estimated fraction of medical costs attributable to diabetes, pd 
represents the prevalence of diabetes, and RR represents the ratio of medical costs for 
people with diabetes to medical costs for those without diabetes. The amount of medical 
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costs attributable to diabetes is then calculated as AF multiplied by total medical costs or 
expenditures. 
We applied this general approach to estimate the costs attributable to diabetes for medical 
services used by the noninstitutionalized and for nursing home costs. To estimate state 
health expenditures attributable to diabetes, we used the 2008 NHEA from CMS. We used 
the 2008 data file, because it was the most recent year for which we had access to both 
NHEA and State Health Expenditure Account (SHEA) data. From the SHEA, we used total 
medical expenditures by state of residence, including administrative costs and medical 
spending. National expenditures are available by age group, sex, payer (Medicaid, Medicare, 
or Other [which includes private insurance paid, out-of-pocket payment, and other payer 
paid]), and types of service (ambulatory care, hospital care, prescription drugs, nursing 
home care, durable medical equipment, and other care [including home health, 
nonprescription drugs, and nondurable medical products]). The expenditures by state in the 
SHEA are available by payer and type of service but not by age group and sex. 
To obtain state expenditure estimates by age group, sex, payer, and service type, we 
allocated state aggregate expenditures across age group, sex, payer, and service type 
categories. Specifically, we started with data from the SHEA. We then estimated diabetes-
attributable costs by age group, sex, payer, and service type and summed these to state 
and national levels for reporting in the Burden Toolkit by using the information from the 
NHEA. We organized our approach around four major tasks: 
1. Estimate state expenditures by age group, sex, payer, and service type 
2. Estimate state prevalence of diabetes (pd) 
3. Estimate diabetes cost ratios (RR) 
4. Estimate diabetes-attributable cost 
2.2.2.1 Estimate State Expenditures by Age Group, Sex, Payer, and Service Type 
Although health care spending likely varies by age group, sex, payer, and service type, the 
SHEA does not provide data broken down for all of these categories. Table 2-4 shows the 
availability of national- and state-level expenditure data for each of these categories. At the 
national level, both total and per capita spending are available for each category. At the 
state level, however, only total and service-level spending are available by payer. An 
algorithm is required to estimate state health expenditures by age group, sex, payer, and 
service type, as described briefly in this section. 
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Table 2-4. National Health Expenditure Accounts and State Health Expenditure 
Accounts Data Available by Category 
Level/Payer 
Total 
Spending 
Spending by 
Age Group, 
Sex 
Spending by 
Service Type 
Spending by 
Age Group, 
Sex, and 
Service Type 
National Y Y Y Y 
Medicare Y Y Y Y 
Medicaid Y Y Y Y 
Private Health Insurance Y Y Y Y 
Other + OOP Ya Ya Ya Ya 
State Y   Y   
Medicare Y   Y   
Medicaid Y   Y   
Private Health Insurance Y       
Other + OOP Ya       
Private Health Insurance 
+ Other + OOP 
Ya   Ya   
a Residual of national or state minus available payers. 
Note: Other=other payers; OOP=out-of-pocket payments for insured and uninsured. 
First, we obtained NHEA and SHEA data on aggregated Personal Health Care expenditures 
for 2008 for the following strata: 
1. Age, in years: 
a. 0–18 
b. 19–44 
c. 45–64 
d. 65–84 
e. 85+ 
2. Sex: 
a. Male 
b. Female 
3. Payer1: 
a. Medicaid 
b. Medicare (fee-for-service and managed care) 
                                           
1 SHEA includes only state-aggregated health expenditures for the privately insured and does not 
break down private health expenditures by age, sex, or service type. Hence, we limited our “cost by 
payer” analysis to include only the three original SHEA payer categories (Medicare, Medicaid, other). 
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c. Other payers and programs 
d. Out-of-pocket (OOP) 
e. Private health insurance 
4. Service Type: 
a. Dental services 
b. Durable medical equipment 
c. Home health care 
d. Hospital care 
e. Nursing care facilities and continuing care retirement communities 
f. Other health residential and personal care 
g. Other nondurable medical products 
h. Other professional services 
i. Physician and clinical services 
j. Prescription drugs 
To estimate 2008 state expenditures by age group, sex, payer, and service type, we used a 
multi-step process, as summarized below: 
1. Calculated per-capita 2008 NHEA costs by age group, sex, payer, and service type. 
2. Developed per-capita 2008 NHEA cost estimates by payer and service type. 
3. Created an adjustment index equal to 2008 state per capita spending by payer and 
service type relative to national per capita spending by payer and service type. 
4. Multiplied this adjustment index by 2008 NHEA spending by age group, sex, payer, 
and service type. 
We collapsed categories to the following stratifications to provide a sufficient sample size for 
estimating all components needed for the state diabetes-attributable cost calculation: 
1. Age: 
a. 19–64 
b. 65+ 
2. Payer (to be consistent with state-level payer type): 
a. Medicaid 
b. Medicare 
c. Other than Medicare and Medicaid (Note: This includes private health insurance + 
other payers + OOP payments for insured and uninsured patients.) 
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3. Service Type: 
a. Hospital care 
b. Ambulatory, including physician and clinical services, other professional services 
c. Prescription drugs and other nondurable medical products 
d. Other, including dental services, durable medical equipment, home health care, 
and other health residential and personal care 
The next steps were to calibrate the estimated total 2008 state expenditures at the age 
group, sex, payer, and service type levels so that the aggregated cost estimates matched 
the 2008 actual total expenditures from SHEA. We then inflated the state health spending 
from 2008 to 2013 using historical expenditure growth from NHEA and calibrated estimates 
to ensure that the sum across all 2013 state estimates matched 2013 national health 
expenditures. After reviewing the state estimates, we changed our approach for imputing 
Medicaid spending, because the imputation method described above was not performing 
well, in the sense that the age group and sex imputation based on national per-capita 
spending could not account for the large geographic variation across Medicaid programs in 
different states. This variability suggests that program benefit design and eligibility criteria 
are more important drivers of Medicaid spending than beneficiary age and sex. To estimate 
2013 state Medicaid costs, we used publicly available 2011 data from the Kaiser Family 
Foundation (KFF) on state Medicaid enrollment groups (Children [0–18], Disabled [0–64], 
Adults [19–64], and Aged [≥65]) and spending by enrollment group (KFF, 2011). Because 
the KFF state Medicaid enrollment and spending data by enrollment group did not 
differentiate spending by service type, we combined spending across the four types of 
services in the 2008 Medicaid spending data from SHEA. We inflated the Medicaid costs to 
2013 using NHEA projected growth in expenditures.  
2.2.2.2 State Diabetes Prevalence 
We used BRFSS data to estimate state diabetes prevalence by age group, sex, and payer, 
using an approach similar to that described in Section 2.1 (CDC, 2014). For this estimation, 
we first assigned payers using data from the 2013 BRFSS core question and module 
questions on health care access. All BRFSS respondents were asked the core question, “Do 
you have any kind of health care coverage, including health insurance, prepaid plans such 
as HMOs, government plans such as Medicare, or Indian Health Service?” We combined this 
information with responses from the Health Care Access BRFSS module question, “Are you 
CURRENTLY covered by any of the following types of health insurance or health coverage 
plans?,” to identify respondents who reported having Medicare, Medicaid, private insurance, 
and/or other third party or out-of-pocket payments for health care. Because only 37 states 
and DC asked the module question on health care, we imputed payer type of Medicare and 
Medicaid for the other 13 states using a chained imputation approach. We then estimated 
diabetes prevalence by payer, by age group (19 to 64 and 65 or older), and by sex for each 
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state. We used overall state diabetes prevalence by age group and sex to represent 
prevalence among those with payers other than Medicare or Medicaid. 
2.2.2.3 Diabetes Cost Ratios 
We generated diabetes cost ratios to estimate the impact of having diabetes on annual 
health care spending by type of service. We generated a diabetes cost ratio, which is the 
ratio of predicted costs for people with diabetes over predicted costs for people with 
diabetes under the scenario in which they do not have diabetes (i.e., a recycled prediction 
approach) using multivariate regression analysis. 
Ideally, cost ratios would have been calculated for each state. However, we lacked 
comprehensive data containing all the variables needed to calculate diabetes cost ratios, 
including diabetes disease indicator, confounding variables such as socioeconomic variables 
and other risk factors, and health care expenditures by types of service, as well as the state 
indicator that allows for state-specific cost ratios to be calculated. Although the MEPS 
restricted file has the majority of these required variables and the state indicator, it requires 
an involved application process and contains only 29 large states that may also encounter 
sample size issues when calculating cost ratios at the level of granularity needed for this 
analysis. Using claims data would have been another possibility. However, claims data do 
not contain socioeconomic variables or other risk-factor variables (e.g., smoking status and 
obesity). Additionally, obtaining approval to use Medicaid and Medicare claims data takes 
additional time and resources. For these reasons, we used the MEPS publicly available file to 
calculate cost ratios by age group, sex, payer, and type of service (all services combined for 
Medicaid) (AHRQ, 2009). 
We used the 2008 to 2012 MEPS to calculate, for each individual survey respondent, annual 
spending by type of service and payer, as shown in Table 2-5. Table 2-5 shows the 
crosswalk of service types between MEPS and NHEA. 
Although MEPS asks detailed questions on respondents’ insurance coverage, we could not 
use these insurance indicators directly because in NHEA and SHEA, spending was separated 
by payer rather than by the primary insurance. We therefore identified the denominator 
population for the analysis involving Medicare and Medicaid payers as those who responded 
as having Medicare or Medicaid as their primary insurance for at least 1 month during the 
year or those who did not self-identify as having Medicaid or Medicare, but who appeared to 
have payments made by Medicare or Medicaid on any of their health care encounters. To 
calculate cost ratios for other payers (including private insurance, out-of-pocket payment, 
and all other payers), we used the entire population from the household consolidated file as 
the denominator for the analysis. 
Section 2 — Data and Methods 
2-19 
Table 2-5. Medical Expenditure Panel Survey (MEPS) Spending and Payer 
Categories for Diabetes Cost Ratio Analysis 
Types of 
Service 
for This 
Analysis 
MEPS Service 
Categories 
SHEA Service 
Type Category 
Medicare 
Paid 
Medicaid 
Paid 
Other 
Paid 
Private 
Plan 
Paid 
Hospital 
inpatient 
Hospital inpatient Hospital care X X X X 
Ambulatory 
care 
Emergency room visits, 
outpatient visits, and 
office-based provider 
visits 
Physician and 
clinical services, 
Other professional 
services 
X X X X 
Pharmacy 
and non-
durable 
medical 
equipment 
Prescription medication 
and nondurable medical 
equipment from other 
medical expenses 
Prescription drugs, 
Other nondurable 
medical products 
X X X X 
Other Dental, vision, home 
health, and durable 
medical equipment from 
other medical expenses 
Dental services, 
durable medical 
equipment, home 
health, other health 
residential, and 
personal care  
X X X X 
Notes: MEPS = Medical Expenditure Panel Survey; NHEA = National Health Expenditure Accounts; 
SHEA = State Health Expenditure Accounts.  
Although NHEA and SHEA include nursing care facilities and continuing care at retirement 
communities, these costs are not included in the MEPS. Hence, the attributable nursing home cost 
was calculated using a different approach (see Section 2.2.2.5). 
Although NHEA includes only spending incurred in free-standing emergency centers in the physician 
and clinical services category, we were not able to distinguish free-standing emergency room visits 
from hospital-based emergency department visits in MEPS. Hence, we included emergency room 
related costs in MEPS in the Ambulatory Care category. 
We do not need the cost ratios for private insurance payer for attributable cost calculation because the 
SHEA does not have detailed spending by private payers. However, we calculated the cost ratios for 
private paid anyway along with Medicare, Medicaid, and Other for flexibility. 
Nursing care facilities and continuing care retirement communities were excluded from this 
part of the analysis because MEPS does not include data for individuals residing in nursing 
homes or other institutions. The nursing home costs attributable to diabetes were instead 
estimated using the Minimum Data Set (MDS) collected by CMS, as described in 
Section 2.2.2.5. 
Using multivariate regression analysis, we estimated the cost ratios by age group (19 to 64 
or 65 or older), sex, and payer. The denominator populations for Medicare and Other had 
sufficient sample sizes to calculate cost ratios by service type. However, for Medicaid, we 
calculated a single cost ratio (i.e., not by service type). 
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Multivariate regressions controlled for confounding factors, including age, age squared, sex, 
race/ethnicity (white, black, Hispanic, Asian, other), poverty status (poor, near poor, middle 
income, and high income), education (no degree, high school graduate, college graduate, 
master/doctoral graduate, other), and Census region (East, Midwest, South, West). We also 
included a variable on the number of months a person was continuously covered by a 
particular insurance in the regressions for Medicare and Medicaid to adjust for lengths of 
coverage. As recommended by the Expert Advisory Panel, we did not control for 
comorbidities. 
The cost data are highly skewed and include many nonusers of the health care system with 
zero spending as well as users who have high spending. We used two-part models that 
included a logit model in the first part and a GLM with a log-link and gamma distribution in 
the second part. This model was selected after examining the distribution of the cost 
variables, looking at model goodness-of-fit statistics, as well as analyzing the results of the 
family link test. 
The cost ratio for individuals in age group a, sex s, payer p, and, service type t was 
estimated as follows (Equation 6): 
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where RRa,s,p,t is the cost ratio for individuals in age group a, sex s, payer p, and, if 
applicable, service type t; Ea,s,p,t(DM=1|DM) is the expected expenditures for people with 
diabetes; and Ea,s,p,t(DM=0|DM) is the expected expenditures for people with diabetes under 
the counterfactual where they do not have diabetes. 
2.2.2.4 Calculating Medical Costs, Except Nursing Home Costs, Attributable to 
Diabetes 
Using diabetes prevalence at the state level by payer and age group described in Section 
2.2.2.2 and the cost ratios at the national level by payer, age group, and type of service 
(except Medicaid) described in Section 2.2.2.3, we calculated the AF of costs attributable to 
diabetes for each payer, type of service (all services combined for Medicaid), and age group. 
The usual AF formula is as follows: 
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where AF is the AF for diabetes costs, RR is the diabetes cost ratio, and pd is the state 
prevalence of diabetes. The subscript j indicates age group, payer, and service type. 
Section 2 — Data and Methods 
2-21 
Equation 7 can be rewritten as follows: 
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Now Equation 9 can be rewritten as Equation 10 by introducing the cost concept to calculate 
the total attributable cost Yj: 
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where C0DM is the per-person spending for a person with diabetes under the counterfactual 
that they do not have diabetes, and CnoDM is the per-person spending for a person who does 
not have diabetes. The first term in the denominator is the diabetes-attributable costs for 
persons with diabetes, the second term is the “regular” nondiabetes-attributable costs for 
persons with diabetes, and the last term is the costs for persons without diabetes. 
A subtle, implicit, and important assumption in the usual formula for AF (Equation 7) is that 
C0DM = CnoDM. However, in the way we calculated C0DM as described in Section 2.2.1.4, it is 
different from CnoDM. Hence, the implicit assumption would be violated if we were to use the 
usual AF formula directly, which can lead to either overestimates or underestimates of 
costs. Therefore, we adjusted the usual AF formula to account for this. 
The cost ratio between C0DM and CnoDM can be defined as follows: 1+φ= C0DM ÷ CnoDM, 
meaning that C0DM=CnoDM × (1+φ). Now Equation 10 can be rewritten as follows: 
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Canceling off the CnoDM term in both the numerator and the denominator, Equation 11 
becomes 
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We applied this adjusted AF Equation 12 to the aggregated state expenditure estimates 
described in Section 2.2.2.1 to calculate diabetes-attributable cost. We calculated diabetes 
attributable direct medical costs by state, age group (19 to 64 and 65 or older), sex, payer, 
and type of service (all services combined for Medicaid) for 2013. 
2.2.2.5 Nursing Home Costs 
We used the CMS MDS and the estimates of state nursing home expenditures by age group, 
sex, and payer described in Section 2.2.2.2 to estimate state-level diabetes-attributable 
nursing home costs by age group, sex, and payer (CMS, 2016). 
Calculate the Diabetes AF for Nursing Home Costs. We first calculated the AF for nursing 
home costs by age group and sex as the excess diabetes prevalence in nursing homes 
compared to the community, as shown in Equation 13: 
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 (13) 
where AF represents the excess diabetes prevalence in nursing homes compared with the 
community, ND is the number of nursing home residents with diabetes, NN is the number of 
nursing home residents without diabetes, RUGD is the average Resource Utilization Group 
(RUG) payment for nursing home residents with diabetes, RUGN is the average RUG 
payment for residents without diabetes, and CD is the prevalence of diabetes in the 
community (CMS, 2009). The number of nursing home residents by diabetes status was 
estimated from the MDS data using a data reference period of April 2013 to May 2015. In 
calculating the RUG-weighted AF in Equation 13, we included only long-term stay residents 
(residents with nursing home episodes of at least 100 days). Episodes were defined 
according to the MDS User Manual’s definition and can span multiple nursing home stays 
that may be separated by brief time intervals where the resident is discharged (CMS, 2015). 
We weighted the number of nursing home residents by the mean RUG payments over the 
same reference period to capture the higher potential cost of people with diabetes. Our 
estimates of diabetes prevalence in the community are from BRFSS 2013 and use the same 
estimation approach as described in Section 2.1.2. 
Estimate Nursing Home Costs by Age Group, Sex, and Payer. As described in Section 
2.2.2.1, we estimated 2013 state-level nursing home costs by age group, sex, and payer. 
Because continuing care retirement communities (CCRCs) are included in the “Nursing Care 
Facilities and Continuing Care Communities” cost category of SHEA but are not considered 
to provide ongoing nursing care, we discounted state-level nursing homes costs by the 
national percentage of payments from CCRCs. 
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Calculate Diabetes-attributable Nursing Home Costs. We multiplied the nursing home AF by 
state nursing home costs to estimate diabetes-attributable nursing home costs by state, age 
group, sex, and payer. 
2.2.2.6 Total Medical Costs 
We added the diabetes-attributable nursing home costs to the diabetes-attributable medical 
costs among the noninstitutionalized population to estimate medical costs of diabetes by 
age group, sex, and payer. These medical cost estimates are provided in the medical cost 
section of the Burden Toolkit and reflect medical spending and administrative costs for 
ambulatory care, hospital care, prescription drugs, nursing home care, durable medical 
equipment, and other care. 
2.2.3 Indirect Cost of Diabetes 
This section of the Burden Toolkit reports diabetes-attributable indirect costs and consists of 
costs of absenteeism, presenteeism, household productivity losses, inability to work, and 
premature mortality. In this section, we describe the methods used to estimate each 
component of the indirect costs of diabetes. 
2.2.3.1 Total Costs 
We calculated total morbidity costs attributable to diabetes as a sum of diabetes-
attributable costs of work absenteeism, work presenteeism, household productivity losses, 
and inability to work. We calculated total indirect costs attributable to diabetes as a sum of 
diabetes-attributable morbidity and mortality costs. We calculated per capita costs as the 
cost per person with diabetes, where the count of people with diabetes includes the 
noninstitutionalized population from BRFSS and nursing home residents. 
2.2.3.2 Absenteeism Costs 
Absenteeism cost is the cost of workdays lost. To estimate the diabetes-attributable 
absenteeism costs among those who are currently employed, we first estimated the number 
of workdays missed that are attributable to diabetes. We estimated the diabetes-
attributable workdays missed per person with diabetes by Census region, age group, and 
sex. We then valued these workdays missed using national age group- and sex-specific 
earnings adjusted to the state level using a state-to-national adjustment factor. We next 
multiplied the value of the workdays missed by estimates of the number of employed people 
with diabetes in each state, by age group, and sex. The steps below provide additional 
details on our approach. 
Step 1: Estimated work loss days attributable to diabetes. We used the National Health 
Interview Survey (NHIS) to estimate the number of work loss days attributable to diabetes 
(CDC, June 2016). NHIS is a cross-sectional household interview survey administered by 
CDC that was designed with a goal to monitor the health of the U.S. population through the 
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collection and analysis of data on a broad range of health topics. The survey covers the 
civilian noninstitutionalized population residing in the United States at the time of the 
interview. 
Pooling data from the 2009 through 2013 NHIS, we estimated work loss at the regional 
(Census region) and national levels. We used regional estimates instead of state-specific 
estimates because person-level state identifiers are not included in the NHIS public use data 
files. In NHIS, we identified persons with diabetes using the question “Have you ever been 
told that you have diabetes?” The work-loss analysis was restricted to individuals employed 
at any point during the year. Number of workdays lost was defined using the following 
question: “During the past 12 months, about how many days did you miss work at a job or 
business because of illness or injury (do not include maternity leave)?” To estimate 
workdays lost due to diabetes, we tested four different models for best fit: one-part 
negative binomial model, two-part truncated negative binomial model with a logit, two-part 
GLM with a logit, and a zero-inflated negative binomial model. Based on a comparison of the 
model residuals, the Akaike information criterion (AIC), and the Bayesian information 
criterion (BIC), our final estimation used a two-part model with a logit model for the first 
part and a GLM for the second part: 
  (14) 
  (15) 
where Missed_Work0 indicates whether a workday was missed in the last year due to illness 
or injury, Missed_Workt denotes the annual number of workdays missed because of illness 
or injury if at least 1 workday was missed, Diabt denotes whether the person has diabetes, 
Comorbidt represents the presence of other comorbidities, Regiont represents region of 
residence (Census region), and Xt denotes sociodemographic characteristics. We used a 
gamma distribution and log link to model the number of missed workdays for those with 
nonzero missed workdays. We controlled for the following comorbidities: arthritis, asthma, 
cancer, depression, chronic bronchitis, back problems, and pregnancy. To capture work loss 
attributable to diabetes and its complications, we did not control for diabetes risk factors 
and complications, such as CHF, CHD, other heart diseases, hypertension, renal failure, 
stroke, and high cholesterol. We also included the following sociodemographic controls: age, 
age squared, race/ethnicity, education, family income, health insurance, and occupation. 
We estimated diabetes-attributable per-person number of workdays missed, calculated by 
age, sex, and region, as the mean difference between the predicted number of workdays 
missed for a person with diabetes and the predicted number of workdays missed for that 
person, assuming no diabetes. We estimated predicted values using coefficients from both 
the logit and GLM models. Note that productivity losses for employed individuals on short-
term disability are captured in this portion of the analysis. 
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Step 2: Obtained earnings estimates by age group/sex/state. Earnings data were not 
available by all three stratifications (age group/sex/state), so we used a two-step approach 
to convert national wage estimates by age group/sex to state-level estimates by age 
group/sex. First, we obtained mean per-capita earnings by age group and sex from the 
Current Population Survey (CPS) Table Creator to estimate daily earnings (CPS, 2016). We 
used 2015 CPS earnings data, which reflect annual earnings from 2014 and include income 
from wages, salaries, and self-employment. Average earnings were estimated by 5-year age 
groups and sex and included full-year full-time workers, part-year full-time workers, full-
year part-time workers, and part-year part-time workers. For consistency with the direct 
medical cost estimates, we used the Bureau of Economic Analysis (BEA) Price Indexes for 
GDP to deflate the annual earnings from 2014 to 2013 dollars (U.S. BEA, 2016). 
Second, we used 2014 national and state-level occupational employment mean wage 
estimates from the BLS to estimate a state-to-national wage ratio (OES, 2016). BLS 
estimates are collected from employers and provide occupation-level wages by state, but 
they are not available by age and sex. We applied the BLS state-to-national wage ratios to 
the CPS national wages by age and sex to obtain state-level wage estimates by age and 
sex. We weighted the 5-year age groups from the CPS annual earnings data to our age 
groups (18–44, 45–64, 65–74) using 2014 Census population estimates (U.S. Census 
Bureau, 2015). We calculated mean earnings per day of work by dividing annual mean 
earnings by 250, which is the typical number of week days worked per year for full-time 
employees. 
Step 3: Calculated per-capita diabetes-attributable absenteeism costs. We calculated state-
level per-capita diabetes-attributable absenteeism costs by age and sex 
(Per_Cap_Missed_Work_Costsag) as follows: 
  (16) 
where Work_loss_Diabrag represents the number of workdays lost attributed to diabetes by 
region, age, and sex (from the NHIS analysis), and Daily_Earnsag represents state-level age 
group- and sex-specific average daily earnings. 
Step 4: Estimated the number of people with diabetes who are employed. We used 2011 
through 2013 NHIS data to calculate the percentage of people with diabetes who are 
employed by region, age group, and sex (CDC, June 2016). We identified employed 
individuals using the same methodology as in Step 1. We estimated the number of 
employed people with diabetes in each state, by age and sex (Diab_worksag), as follows: 
  (17) 
where Perc_employ|diabsag denotes the region, age group-, and sex-specific percentage of 
people with diabetes who are employed, as estimated from NHIS. Num_diabsag represents 
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the number of people with diabetes by state, age group, and sex, which we obtained from 
the Health Burden section of the Burden Toolkit. 
Step 5: Calculated total absenteeism costs. Our final step was to calculate total absenteeism 
costs by age group and sex for each state, as follows: 
  (18) 
For this calculation, we multiplied the per-capita cost of missed work attributable to 
diabetes (Per_Cap_Missed_Work_Costsag) by an estimate of the total number of people in 
the state, by age and sex, who have diabetes and are employed (Diab_worksag). 
In the Burden Toolkit, we report per capita annual work absenteeism costs calculated as 
cost per employed person with diabetes and as cost per person with diabetes, where 
persons with diabetes include the noninstitutionalized population from BRFSS and the 
nursing home residents. 
2.2.3.3 Presenteeism Costs 
Presenteeism cost is the cost of on the job productivity losses. To estimate the costs of 
reduced productivity while at work, we used published estimates of the impact of diabetes 
on reducing productivity. In the American Diabetes Association (ADA) analysis, the authors 
assumed that, on average, 6.6% of annual productivity is lost while people are at work as a 
result of diabetes (ADA, 2013). We multiplied this reduced productivity estimate by state-
level daily earnings by age group and sex (Daily_Earn_per_capsag; estimated in Step 2 in 
Section 2.2.3.2) and then applied it to the average number of days worked by employed 
people with diabetes minus the number of days missed by people with diabetes, as follows: 
  (19) 
where Daily_Earn_per_cap denotes daily CPS earnings data (annual earnings divided by 250 
days), which are the same data we used to estimate absenteeism costs, thus consistently 
valuing productivity losses from absenteeism and presenteeism. Days_Missed_Workag is the 
average number of days of work loss among people with diabetes by age group and sex. 
Because presenteeism costs apply only to employed people with diabetes, we used data on 
employment among people with diabetes to estimate total state costs of presenteeism. For 
each state, age group, and sex, we multiplied per capita presenteeism costs by the 
estimated number of employed individuals with diabetes from NHIS 2011–2013. We 
identified employed individuals using the same methodology as in Step 1 in Section 2.2.3.2 
(those who had a job in the last week or no job in the last week but a job in the past 12 
months were identified as employed). In the Burden Toolkit, we report per capita annual 
work presenteeism costs calculated as cost per employed person with diabetes and as cost 
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per person with diabetes, where persons with diabetes include the noninstitutionalized 
population from BRFSS and the nursing home residents. 
2.2.3.4 Household Productivity Losses 
Household productivity losses arise when people are unable to perform household services. 
Although our absenteeism costs value lost market production due to diabetes, these 
estimates do not value lost non-market production due to diabetes. We estimated 
household production losses using the number of days spent in bed attributable to diabetes 
to value non-market production lost due to diabetes, such as housework, food cooking and 
clean-up, household management, caring for children in the household, etc. To estimate the 
number of bed days attributable to diabetes, we used NHIS and the same methodology that 
we used to estimate the number of workdays lost for the absenteeism cost analysis. 
However, because both employed and unemployed individuals may experience bed days, 
the bed days analysis included all respondents aged 18 or older, regardless of whether they 
were employed. For an employed individual, a sick day spent in bed would result in losses in 
both labor and household productivity. Consequently, valuing both labor and household 
productivity losses for a missed workday spent in bed does not result in double counting of 
costs. 
Step 1: Estimated bed days attributable to diabetes. We defined number of days spent in 
bed using the following NHIS question: “During the past 12 months, about how many days 
did illness or injury keep you in bed more than half of the day? (include days while an 
overnight patient in a hospital).” Using 2009–2013 NHIS data, we tested four different 
regression models for best fit: one-part negative binomial, two-part truncated negative 
binomial with a logit, two-part GLM with a logit, and a zero-inflated negative binomial 
model. Based on a comparison of the model residuals, the AIC, and the BIC, our final bed 
days estimation used a two-part model with a logit model in the first part and a GLM in the 
second: 
  (20) 
  (21) 
where Bed_Days0 indicates whether at least 1 bed day was reported, Bed_Dayst denotes the 
annual number of bed days reported if at least one day was spend in bed, Diabt represents 
whether the individual has diabetes, Comorbidt represents the presence of other 
comorbidities, Regiont represents region of residence (Census region), and Xt represents 
other sociodemographic characteristics. We used a GLM with a gamma distribution and a log 
link to estimate the number of bed days for those with nonzero bed days. We controlled for 
the following comorbidities: arthritis, asthma, cancer, depression, chronic bronchitis, back 
problems, and pregnancy. To capture the downstream effects of diabetes, we did not control 
for diabetes risk factors and complications, such as CHF, CHD, other heart diseases, 
Diabetes State Burden Toolkit 
 
2-28 
hypertension, renal failure, stroke, and high cholesterol. We also included the following 
sociodemographic controls: age, age squared, race/ethnicity, education, family income, 
health insurance, and employment status. We estimated diabetes-attributable per person 
number of days spent in bed, calculated by age and sex at the regional level, as the mean 
difference between predicted number of bed days for each person with diabetes and the 
predicted number of bed days assuming no diabetes. We estimated predicted values using 
coefficients from the GLM and logit models. 
Step 2: Valued a lost day of household production. We obtained an estimate of the average 
per capita monetary value of a day of household production by age group and sex from the 
Expectancy Data Economic Demographers’ “Dollar Value of a Day, 2013” publication 
(Expectancy Data, 2014). That report provides a market estimate of the value of a day for 
various activities, including household production and caring for and helping others in the 
household, such as inside housework, food cooking and clean-up, shopping, and household 
management. The estimates are based on time-diary data from BLS’ American Time Use 
Survey, combined with data from a wage survey conducted by BLS. These value-of-time 
estimates are available at the national level only. We adjusted the age group and sex-
specific estimates to state estimates by creating state multipliers using BLS 2015 average 
wages for each state, by age group and sex, as a ratio of average national wages, by age 
group and sex (see Step 2 in Section 2.2.3.2 for further details about the state multipliers). 
Step 3: Calculated per-capita diabetes-attributable household productivity costs. We then 
calculated state-level per-capita diabetes-attributable household productivity losses by age 
group and sex (HH_prod_loss_PCsag) as follows: 
  (22) 
where Bed_days_diabrag represents the estimated per capita number of bed days 
attributable to diabetes by region, age group, and sex, and HH_daily_valuesag denotes the 
state-level value of a day of household production and caring for and helping others in the 
household, by age group and sex. 
Step 4: Calculated total household productivity costs. We calculated total household 
productivity losses by age group and sex for each state (HH_prod_loss_totsag) as follows: 
  (23) 
where HH_prod_loss_PCsag denotes per capita state-level diabetes-attributable household 
productivity losses by age group and sex. Num_diabsag is the estimated number of people 
with diabetes by age group (a) and sex (g) among the noninstitutionalized in each state (s), 
which we obtained from the Health Burden section of the Burden Toolkit. In the Burden 
Toolkit, the per person household productivity costs are reported per person with diabetes 
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where persons with diabetes include the noninstitutionalized population from BRFSS and 
nursing home residents. 
2.2.3.5 Inability to Work Costs 
Inability to work costs arise when people are disabled and unable to work. If people are too 
sick to work because of diabetes, they lose the full value of their expected earnings over the 
course of a year. We assume that these disabled, unemployed individuals would have been 
employed if they did not have severe diabetes causing them to stop working. Our approach 
to estimating these losses involves first estimating the probability of being unable to work 
because of diabetes by region, age group, and sex, applying this probability to state 
estimates of the number of people with diabetes by age group and sex, and then valuing 
work loss for those unable to work using state-, age group-, and sex-specific annual 
earnings data. We include estimates for the noninstitutionalized population only. 
Step 1: Estimated probability of being unable to work attributable to diabetes. We estimated 
the probability of being unable to work because of diabetes using 2011–2013 NHIS data 
(CDC, June 2016). We defined a person as being unable to work if he or she answered 
“Disabled” to the question “What is the main reason you did not work last week?” We 
estimated the probability of being unable to work because of diabetes at the national level 
by region, age group, and sex, using a logistic regression model, as follows: 
  (24) 
where Unable_to_workt represents whether an individual reports being unable to work 
because of a health condition; Diabt denotes whether the individual has diabetes; Comorbidt 
represents the presence of other comorbidities (e.g., arthritis, asthma), Regiont represents 
region of residence (Census region), and Xt represents other sociodemographic 
characteristics (age, sex). We used coefficients from the model to estimate the mean 
difference in the predicted probability of being unable to work for someone with diabetes 
relative to their predicted probability of being unable to work if they did not have diabetes. 
We estimated the probability of being unable to work because of diabetes by region, age 
group, and sex, denoted as Pr_unable_to_workrag. 
Step 2: Estimated the number of people with diabetes who are unable to work. We 
multiplied the estimated probability of being unable to work because of diabetes (by age/ 
sex) by the number of people with diabetes by state, age group, and sex. This calculation 
resulted in an estimate of the number of people unable to work because of diabetes 
(Num_unable_to_worksag), as follows: 
  (25) 
The estimated number of people with diabetes, or Num_diabsag, was from Section 2.1.2. 
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Step 3: Calculated total inability to work costs. We multiplied the number of people unable 
to work because of diabetes in each state by state-level mean annual earnings by age group 
and sex (estimated in Step 2 in Section 2.2.3.2), as follows: 
  (26) 
where Unable_to_Work_Diab_Costsag represents total state-, age group-, and sex-specific 
costs that arise when people with diabetes are too sick to work, and Annual_Earnsag denotes 
state-, age-group, and sex-specific annual earnings estimates from the CPS. These are the 
same earnings estimates that we used to value absenteeism and presenteeism costs for 
employed people with diabetes (see Step 2 in Section 2.2.3.2 for further details about the 
state-level earnings estimates). 
In the Burden Toolkit, we report per capita annual costs of inability to work calculated as 
cost per person with diabetes who is unable to work and as cost per person with diabetes. 
2.2.3.6 Mortality Costs 
We estimated mortality costs using a human capital approach, which values premature 
death from a disease as future productivity losses foregone (Haddix, Teutsch, and Corso, 
2003; Rice, Hodgson, and Kopstein, 1985; Rice, 1966). Our diabetes-attributable mortality 
cost estimates provide separate estimates for the value of labor productivity losses and the 
value of household productivity losses resulting from premature mortality. We used the 
number of deaths attributable to diabetes by age group and sex in each state estimated in 
Section 2.3.1 and multiplied those estimates by estimates of the present value of lifetime 
earnings and household productivity costs to calculate total mortality costs. 
We estimated labor losses due to premature mortality for adults aged 18 to 74 and 
household production losses due to premature mortality for adults aged 18 to 84. We did 
not calculate labor costs associated with premature mortality for adults aged 75 or older to 
be consistent with other labor loss estimates (absenteeism and presenteeism costs). We did 
not calculate household productivity losses due to premature mortality for adults aged 85 or 
older because we assumed that participation in household activities among this group is 
low. For the mortality cost analysis, we used finer age categories than in other sections of 
the indirect cost estimation to better capture the distribution of deaths within age groups 
and therefore more accurately assign estimates of lost earnings or household productivity. 
The finer age groups were 18 to 34, 35 to 44, 45 to 54, 55 to 59, 60 to 64, 65 to 69, 70 to 
74, 75 to 79, and 80 to 84. We then aggregated the mortality cost estimates into the 
standard age groups used for the rest of the indirect cost estimates (18 to 44, 45 to 64, 65 
to 74, and 75 to 84). 
Step 1: Calculated lifetime earnings and lifetime household production costs. We estimated 
the present value of future earnings and household production using national estimates of 
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annual earnings and the dollar value of household production that we used to value work 
loss and household production losses (described in Steps 2 of Sections 2.2.3.2 and 2.2.3.4). 
Future costs were discounted by the probability of surviving to each year of age at which 
the expected production occurs. We used 2010 U.S. life tables from the National Vital 
Statistics Report to calculate compounded survival rates for each age group (Arias, 2014). 
To ensure that losses were applied only to the populations expected to incur the losses, we 
multiplied the age group- and sex-specific labor costs for each state by age group- and sex-
specific employment rates, and we multiplied age group- and sex-specific percentages of 
people living in households by household production losses by state, age, and sex (Haddix, 
Teutsch, & Corso, 2003). We also adjusted for expected future growth in productivity using 
a 1% annual growth rate and discounted the costs using a 3% annual discount rate, as 
recommended in Haddix, Teutsch, and Corso (2003). We then adjusted these present-value 
estimates to state estimates by multiplying them by the ratio of state-to-national wages 
that we used for the morbidity-related cost estimates. 
Step 2: Calculated total mortality costs. We calculated total mortality costs for each age/sex 
group by multiplying lifetime earnings and lifetime household production costs by the 
number of deaths attributable to diabetes (calculated in Section 2.3.1). We then aggregated 
the mortality costs into the standard age groups used in the rest of the indirect cost 
estimation section. 
2.2.4 Costs by Perspective 
This section of the Burden Toolkit reports diabetes costs from the perspective of the state 
Medicaid program, private insurers in the state, and all employers in the state. The purpose 
of these estimates is to provide different stakeholder groups with estimates of costs or 
losses that they incur as a result of diabetes. The costs reported in this portion of the 
Burden Toolkit are estimates that may be useful to stakeholders for planning their likely 
expenditures, given diabetes prevalence among enrollees or employees and for assessing 
the potential value of investments in approaches to manage or prevent diabetes. 
Stakeholders that are interested in assessing the potential costs and impacts of investing in 
the National Diabetes Prevention Program for enrollees or employees should see the 
Diabetes Prevention Impact Toolkit. 
2.2.4.1 Medicaid Costs 
We obtained state health expenditures paid for by Medicaid (Section 2.2.2.1) from SHEA 
data and allocated Medicaid spending across age and sex groups. We used the state 
Medicaid expenditures for all health care service types, including nursing home costs. As 
described in detail in Sections 2.2.2.4 and 2.2.2.5, we used an AF approach to estimate the 
amount of each state’s Medicaid expenditures attributable to diabetes by age group and 
sex. We provide these estimates as the state Medicaid costs attributable to diabetes, 
showing both total costs and costs per adult with diabetes enrolled in Medicaid. 
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2.2.4.2 Private Insurance Costs 
We estimated annual diabetes-attributable medical costs incurred by private insurers by 
starting with the medical costs paid by payers other than Medicare or Medicaid, including 
private insurers, military insurers, out-of-pocket expenditures, and other payers, as 
described in Section 2.2.2. We then multiplied Other Payer costs by the fraction of these 
costs paid by private insurers, which we calculated for each state from SHEA data. Because 
expenditures from SHEA were not available by age group and sex, we assumed that the 
fraction of Other Payer costs paid by private insurers did not vary by age group or sex. On 
average, about 55% of Other Payer costs were paid by private insurers across all states in 
the SHEA. We did not include nursing home costs in the Other Payer costs because most 
private insurance costs are for the noninstitutionalized. Consequently, our private insurer 
cost estimates reflect costs incurred for the noninstitutionalized population only. We applied 
the state fractions of private payer costs to Other Payer costs by state, age group (19 to 64 
and 65 or older), and sex to estimate total private insurer costs by state, age group, and 
sex. 
To estimate private insurance costs per person with a private payer, we first estimated the 
number of privately insured people with diabetes in each state by age group (19 to 64 and 
65 or older) and sex. We used 2013 BRFSS data to estimate the total number of people in 
each state with a private payer by age group and sex, as described in Section 2.2.2.2, 
where we imputed payer status for states that did not ask the health insurance module 
questions. We then estimated diabetes prevalence among the privately insured by age 
group and sex for each state, also using 2013 BRFSS data. Combining the privately insured 
and diabetes prevalence among the privately insured estimates resulted in estimates of the 
number of privately insured people in each state with diabetes by age group and sex. We 
estimated private insurance costs per person by dividing total diabetes attributable costs 
paid by private payers for each state, age group, and sex by the estimated number of 
privately insured people with diabetes for each state, age group, and sex category. 
2.2.4.3 Employer Costs 
The estimated annual diabetes-attributable costs incurred by employers in each state 
consist of the medical costs paid by private insurers for employees with diabetes and the 
diabetes-attributable indirect costs of absenteeism and presenteeism, which reflect 
productivity losses borne by employers. The medical costs incurred by private insurers serve 
as a fair representation of costs for employers that are self-insured and are a proxy for 
other employers because even though they do not directly pay the private insurance 
expenditures, premiums for a given year are usually negotiated based on previous year’s 
medical expenditures. Our approach for estimating private insurance costs is described in 
more detail in Section 2.2.4.2. To estimate employer costs, we applied per-person diabetes-
attributable private insurance cost estimates to the number of employees with diabetes. 
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This component of employer costs was estimated by state, age group, and sex for all 
employees aged 18 to 74. 
The absenteeism and presenteeism costs attributable to diabetes were drawn directly from 
our estimates of indirect costs of diabetes. Our methods for estimating absenteeism and 
presenteeism costs attributable to diabetes are described in detail in Sections 2.2.3.2 and 
2.2.3.3. For employers’ annual absenteeism and presenteeism costs attributable to 
diabetes, we estimated costs by age group and sex for all employees aged 18 to 74. 
Our estimated employer costs attributable to diabetes reflect total costs incurred by all 
employers in the state and average cost per employee with diabetes in the state. 
2.3 Diabetes Mortality 
This section of the Burden Toolkit reports diabetes mortality estimates in each state and 
nationally and consists of diabetes-attributable deaths, years of life lost (YLLs), and quality-
adjusted life years (QALYs) lost due to diabetes.  
The following annual estimates are reported in the mortality section of the Burden Toolkit at 
the state level and nationally: 
1. Mortality 
a. Number of diabetes-attributable deaths, in total, by sex, by age group, and by 
sex/age group 
i. Diabetes as the underlying cause of death 
ii. Cause-specific deaths attributable to diabetes: all causes of death, CVD 
deaths, and end-stage renal disease (ESRD) deaths 
b. Diabetes-attributable deaths per 100,000 persons, in total, by sex, by age group, 
and by sex/age group 
i. Diabetes as the underlying cause of death, defined as “the disease or injury 
that initiated the chain of morbid events that led directly and inevitably to 
death” 
ii. All causes and cause-specific deaths, including CVD deaths and ESRD deaths 
attributable to diabetes  
2. YLLs, in total and by age group/sex 
a. Estimated average YLLs attributable to diabetes 
b. Number of persons with diabetes (in thousands) 
c. Total YLLs attributable to diabetes (in thousands) 
3. QALYs lost, in total and by age group/sex 
a. Estimated average QALYs lost due to diabetes 
b. Number of persons with diabetes (in thousands) 
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c. Total QALYs lost due to diabetes (in thousands) 
Each measure of the mortality estimates is described in detail in the following subsections. 
2.3.1 Mortality Data 
The mortality section of the Burden Toolkit reports the number and rate per 100,000 of 
diabetes-attributable deaths in persons aged 15 or older.2 The mortality data are presented 
by four age groups (15–44, 45–64, 65–74, 75 or older) by sex and state using 2013 CDC 
Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) mortality data (CDC, 
July 2016). CDC WONDER is a public-use online database for epidemiologic research that 
contains information about mortality (deaths) and census data. Death counts are 
automatically calculated in the CDC WONDER interface and are downloadable by cause, age, 
sex, and state. The Burden Toolkit reports number and rate of deaths with diabetes as the 
underlying cause of death and diabetes-attributable deaths for all causes, CVD, and ESRD 
for 780 (52*5*3) different combinations of states and DC (51 plus the United States as a 
whole), age categories (4 plus overall), and sex (2 plus overall). 
Aggregating up to four age groups to match diabetes prevalence calculated in Section 2.1.2 
drastically decreases the percentage of suppressed or unreliable cohorts. Originally, we 
planned to report deaths attributable to heart disease and stroke/cerebrovascular disease, 
but we could not obtain sufficiently precise estimates of the relative risk for those causes 
separately. So we combined deaths from heart disease and stroke into one group: CVD 
deaths. 
In CDC WONDER, mortality statistics are suppressed when n < 10 for the specified strata 
and are considered unreliable when n < 20; thus, we are not able to report the data for 
these strata in the Burden Toolkit. To minimize the amount of suppressed and unreliable 
data at the state level, aggregation of data was needed for some subgroups. We used the 
following set of rules to aggregate the data.  
For reporting the number of deaths from CDC WONDER, we used the following rules, 
ranking from most desirable to least desirable: 
1. Use 2013 state/age group/sex deaths (100% of observations with all-cause deaths 
are in this category, meaning that we have no unreliable or suppressed data for all-
cause deaths; 97% of CVD deaths; and 83% of diabetes as the underlying cause of 
deaths). 
2. When #1 is suppressed or not reliable, pool state data through 2011–2013 and 
divide by 3 to calculate an average annual death rate (2% of deaths with diabetes as 
the underlying cause falls in this category). 
                                           
2 Herein we start with age 15 to 19 because CDC WONDER reports deaths in 5-year bins. However, for 
QALYs and YLLs, we start at age 18. 
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3. When #1 and #2 do not produce numbers above the reliable threshold, use 2013 
regional death rates and apply to state cohort population (0.2% of CVD deaths; 
0.9% of diabetes deaths). 
4. If #1–3 all yield suppressed numbers, we report “suppressed” in the Burden Toolkit 
(1.5% of CVD deaths; 6% of diabetes deaths).  
5.  If #1–3 all yield unreliable numbers, we report the 2013 state value (#1), but 
caution users that such estimates may be unreliable (1.3% of CVD deahs; 8.1% of 
diabetes deaths). 
2.2.1.2 Attributable Fraction of Diabetes 
Because diabetes is not always listed as a cause of death on death certificates, diabetes-
attributable mortality from all-cause and CVD was calculated using the AF approach. The AF 
approach estimates the number of deaths attributable to diabetes by combining information 
on the prevalence of diabetes, the RR of death for persons with diabetes relative to persons 
without diabetes, and the total number of deaths in the entire population. To do so, we used 
Miettinen’s formula for calculating AF (1974): 
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where p is diabetes prevalence, and RRj is the adjusted RR of disease j (in our case, from all 
causes or CVD) in the diabetes subsample relative to the non-diabetes sample. We used 
diabetes prevalence from BRFSS 2013, stratified by age group, sex, and state. For more 
information on how the diabetes prevalence was estimated for each state, see Appendix A. 
We applied Miettinen’s formula for all-cause and CVD mortality attributable to diabetes 
because CVD is a major diabetes-related causes of death. 
One concern about Miettinen’s formula is that it is not appropriate if adjusted RRs are 
included in the presence of confounding. We partly avoid the problem of confounding by 
stratifying the RR calculation by age group and sex. This is potentially important because 
the prevalence of diabetes increases with age, RRs decrease with age, and overall deaths 
increase with age. Still, some concerns about confounding may remain because our RR 
estimates controlled for race/ethnicity. However, further stratification of mortality data is 
problematic as the count of reliable numbers of deaths, per strata, especially for the 
younger cohorts, markedly decline. RRs were estimated using a logistic regression model, in 
which the dependent variable was a binary variable for death and the independent variables 
were diabetes indicator, age, sex, and race. We validated the RR estimates by noting that 
results from the logistic regression with discrete survival time are not statistically different 
when using and not using race/ethnicity as a control. 
To calculate RR, we used NHIS data as in Gregg et al. (2012) but included more recent 
NHIS base years (2005–2009) and follow-up (using mortality data up to 2011). We 
Diabetes State Burden Toolkit 
 
2-36 
estimated a discrete logistic model stratified by age group (18–44, 45–64, 65–74, and 75 or 
older) and by sex and adjusted for race/ethnicity. 
We computed separate mortality rates for all causes and CVD (Table 2-6). Information from 
the stratification exercise showed that the RR for all-cause mortality declined with age. 
When RRs were not available because no males aged 18 to 44 with diabetes died during the 
study period compared with individuals without diabetes, our best estimate was to assume 
that deaths were equal to zero. 
Table 2-6. Relative Risk (Logit Model) Using 2005–2011 Data 
Sex 
Age Group 
All-Cause 
Mortality Cardiovascular Disease  Mortality 
Corresponding ICD-10 All I00–I09, I11, I13, I20–I51, I60–I69 
Male Age 18–44 3.15 — 
Male Age 45–64 2.90 3.89 
Male Age 65–74 1.90 2.43 
Male Age 75+ 1.26 1.12a 
Female Age 18–44 2.16 9.62 
Female Age 45–64 2.99 3.33 
Female Age 65–74 2.13 2.68 
Female Age 75+ 1.36 1.37 
Source: Relative risks: (diabetes vs no diabetes), by age group/sex were computed by Yiling Cheng 
(CDC). 
Note: Dash (—) indicates no relative risk available (no individuals with the condition died in the 
sample). 
aThis cell (cardiovascular disease, Male 75+) indicates that relative risk is not statistically significant at 
alpha = 0.1. 
We multiplied the AF by the total number of deaths from all causes and CVD deaths to 
estimate the number of diabetes-attributable deaths for all causes and CVD and rounded 
the estimate to the nearest 10. 
Death certificates provide information on both the immediate cause of death (“the final 
disease, injury, or complication directly causing death”) and the underlying cause of death 
(“the disease or injury that initiated the chain of morbid events that led directly and 
inevitably to death”) (CDC, 2016). However, diabetes is under-diagnosed and under-
reported as an underlying cause of death among adults because (a) diabetes is often not 
mentioned on death certificates even among persons known to have diabetes, and (b) it is 
difficult to know whether diabetes caused or was a contributing factor to deaths (Geiss, 
Herman, & Smith, 1995).  
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We also report separately the number of persons with diabetes listed as the underlying 
cause of death on their death certificates. These are downloadable from CDC WONDER. As 
noted above, this number underestimates the number of deaths due to diabetes. 
Nonetheless, it is a number regularly reported by CDC’s National Center for Health Statistics 
(NCHS) and can be viewed as a conservative lower bound estimate of the number of deaths 
due to diabetes. It can also be interpreted within the AF approach where the AF is 1; that is, 
diabetes is the true cause of death for anyone reported to have diabetes as the underlying 
cause of death. 
For ESRD, we used 2013 data from the United States Renal Data System (USRDS) 
(http://www.usrds.org/) to report mortality for individuals diagnosed with diabetes. The 
USRDS is a national data system that collects, analyzes, and distributes information about 
CKD and ESRD in the United States. In the Burden Toolkit, we reported the number of 
deaths from ESRD reported in death certificates among those with diabetes. This assumes 
that all deaths from ESRD in this subpopulation are attributable to diabetes. 
Technically, we used the AF approach for diabetes and ESRD, but we are assumed that the 
AF = 1. Because we independently estimated all-cause deaths and the deaths from the 
three specific causes, there is no guarantee that the estimates satisfy the following 
condition: 
 CVD deaths + diabetes underlying cause+ ESRD deaths < all-cause deaths 
Mortality estimates used data from four different sources (BRFSS for diabetes prevalence, 
NHIS for RR, CDC WONDER for deaths, and USRDS for ESRD deaths). Two of the three 
inputs that go into the AF calculation are estimates: RR and diabetes prevalence. Because 
the relative risk is estimated using national data, rather than state data, there may be a few 
cases where the sum of state estimates across causes may exceed the actual number of 
deaths from all causes. Therefore, it is not surprising that the all-cause mortality was less 
than the sum of mortality for the three specific causes in a small number of cases (48 out of 
780). These are outlined in detail in Appendix A. 
The 48 cases are limited to ages 15 to 44 and 75 or older. The specific reasons for the 
discrepancy between the sum of parts and the total cause of death are as follows: 
▪ In 41 states (plus the United States as a whole), for females aged 15 to 44, the CVD 
RR for this group is much bigger (9.62) than the all-cause RR for the same group 
(2.16). Despite the difference in actual deaths between all-cause and CVD, once we 
apply the AF formula, the numbers of diabetes-attributable CVD and all-cause deaths 
are comparable. For example, the total number of CVD deaths for females aged 15 
to 44 in Ohio equals 288. According to our AF estimations, 53 of these CVD deaths 
are attributable to diabetes. Total deaths from all causes in this cohort equal 1,974. 
Using Equation 1, 59 of these total deaths are attributable to diabetes. 
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▪ In Minnesota, the “excess” deaths among females aged 15 to 44 are enough to push 
the overall (across males and females) cause-specific deaths above all-cause deaths. 
▪ In Hawaii, New Mexico, and Vermont, for males aged 75 or older and in North 
Dakota for women aged 75 or older, the crude counts of deaths with diabetes as the 
underlying cause are relatively large, while the RR for the computed all cause of 
deaths is relatively low (i.e., close to 1) for older individuals. 
▪ In New Mexico, the “excess” deaths among males aged 75 or older are enough to 
push the overall cause-specific deaths among adults aged 75 or older above all-
cause deaths (by 6 deaths). 
2.3.2 Years of Life Lost (YLLs) 
YLL due to diabetes is an indicator of premature mortality and is calculated by multiplying 
the number of persons with diabetes by the difference in life expectancy between people 
with and without diabetes. Using the life table approach, we estimated all-cause mortality 
rates by age and sex and generated a cause-specific life table for diabetes. The cause-
specific life table was constructed using prevalence of diabetes by age (5-year bins) and sex 
(see Appendix Table A-3); all-cause mortality values from CDC’s NCHS by single year of age 
and sex; and national-level RR of mortality (Table 2-6) for those with and without diabetes. 
We estimated YLLs using the life expectancy at the age at which death occurs, using 
Pharaoh and Hollingworth’s (1996) method for scaling all-cause mortality of those with 
diabetes relative to those without diabetes. The scale-up factor, 𝜃𝜃𝜃𝜃, takes into account the 
RR (r) and diabetes prevalence (p) within the existing population as shown in Equation 28: 
                                       ( )ppr
r
u −+
=
1
θ                                          (28) 
The scale-up factor ranges between r and 1. When p is close to zero, 𝜃𝜃𝑢𝑢 will approximate 
to r. 
The corresponding scale-down factor (𝜃𝜃𝑑𝑑) for mortality for persons without diabetes is 
shown in Equation 29:  
                                          ( )pprd −+= 1
1θ                                      (29) 
Using the life table approach, we estimated all-cause mortality rates by age and sex and 
generated a cause-specific life table for persons with diabetes. The cause elimination life 
table was constructed from the death rates (number of deaths per 100,000) by using 
prevalence of diabetes by state, age (5-year bins), and sex; all-cause mortality values from 
CDC’s NCHS by state, age, and sex; and national-level relative risk of mortality for those 
with and without diabetes. 
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In our life table approach, we first obtained the probability of dying between a given age x 
and age x+1 (this probability is commonly denoted as qx). The information on qx for all 
cause conditions was obtained from published 2010 CDC tables.3 
  (30) 
We then estimated the number of person years lived (denoted as Lx) between age x and 
x+t, assuming that deaths are evenly distributed, as follows: 
 
( )
( )[ ] ( )tx
Lx
=∗
=
 Age Alive Persons ofNumber 2Interval Time
 lived years person ofNumber 
 (31) 
Assuming a cohort of 100,000 births, we calculated the total number of person-years that 
would be lived after the beginning of the indicated age interval by cumulating the number of 
person-years lived from the oldest to the youngest age. The average remaining lifetime (in 
years) for a person who survives to the beginning of the indicated age interval was 
calculated by dividing the total number of person-years lived from age x (Tx) by the number 
of persons alive at age x (lx) (i.e., ex = Tx/lx). For deaths that occurred within the age 
interval x and x+n, the crude expected YLL equals the longest life expectancy for each 
cohort in the absence of diabetes minus the life expectancy with the condition. YLLs due to 
diabetes is then averaged across each age group. Total and 18+ age group estimates 
represent the weighted average of the age/sex group estimates, where the weights 
represent the relative share of persons with diabetes accounted for by each sex and age 
group by state. Because prevalence estimates by age are not available for the same level of 
granularity as the life tables (1 year of age intervals), we assume the same weight (=1) to 
each age in the age group (18–44, 45–64, and 65–74 age groups). For the 75+ age group, 
because the relative age share starts to decline after age 90, we calculated the average 
YLLs through age 89–90 only. However, although the average YLLs for the 75+ strata only 
include diabetes counts from ages 75–76 through 89–90 in the calculation, the underlying 
YLLs (and QALYs for each age) calculation accounts for the full age set, following standard 
life tables, including losses through age 100. 
2.3.3 Quality-Adjusted Life Years Lost 
QALYs is a measure that combines quality of life (QoL) and life expectancy. QoL is measured 
on a scale from 0 to 1, where 0 represents death and 1 represents perfect health. The 
rationale for computing QALYs is to account for mortality and morbidity by assigning patient 
utility values to health states and then summing utility values for each period over an 
appropriate time horizon (e.g., a person’s remaining life expectancy). We computed QALYs 
using BRFSS survey data and Jia and Lubetkin’s (2008) mapping to obtain preference-based 
values for the EuroQol five-dimensional (EQ-5D) questionnaire index, based on respondents’ 
                                           
3 At the time of the analysis, the most recent published numbers were from 2010: 
http://www.cdc.gov/nchs/data/nvsr/nvsr63/nvsr63_07.pdf 
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answers to the BRFSS Healthy Days (HD) questions. This allowed us to estimate average 
patient utility levels for persons with diabetes and compare that utility to persons without 
diabetes using BRFSS. 
We estimated QALYs using the following three steps: 
1. Aggregated responses to the physical and mental HDs questions to obtain an overall
measure of unhealthy days (UDs). Transformed these into remaining HDs in a month
for each participant and aggregate values by age and sex.
2. Mapped HDs into EQ-5D values using Jia and Lubetkin’s (2008) table.
3. Calculated survival probabilities by age and sex.
These steps are outlined in detail in the sections below. 
2.3.3.1 Unhealthy Days and EQ-5D 
The BRFSS included the HD measures between 1993 and 2013. The HD measures asked 
respondents to report the number of days in the past 30 days when they had physically 
unhealthy days (PUDs) and mentally unhealthy days (MUDs). The questions are phrased as 
follows: 
▪ Thinking about your physical health, which includes physical illness and injury, for
how many days during the past 30 days was your physical health not good?
▪ Thinking about your mental health, which includes stress, depression, and problems
with emotions, for how many days during the past 30 days was your mental health
not good?
We used 2013 BRFSS data. Physical and mental HD questions were available for all 50 
states and DC in the 2013 BRFSS. Both questions required the respondent to answer with a 
number between 0 and 30. The overall UD measure was calculated by adding together a 
respondent’s PUDs and MUDs with a logical maximum of 30 UD (Equation 32): 
( )MUDPUD += ,30 minimumDays Unhealthy (32) 
To assess the heath-related QoL, we transformed our UD estimates to EQ-5D scores. The 
EQ-5D is the most widely used generic preference-based measure of health-related QoL. The 
EQ-5D is a descriptive system covering five dimensions—mobility, self-care, usual activity, 
pain/discomfort, and anxiety/depression—that each have three levels: no problem, some 
problems, and extreme problems. We used the mapping algorithm provided by Jia and 
Lubetkin (2008) to translate HDs into EQ-5D scores as shown in Appendix A. We calculated 
HD from BRFSS UD by subtracting respondents’ PUDs and MUDs from 30 days, with a 
logical maximum of 30 HDs (Equation 33). HDs were calculated by state, age category, and 
sex. We used the same age categories as the Health Burden section and the Diabetes 
Mortality section (18–44, 45–64, 65–74, and 75 or older). 
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 ( )MUDPUD +−= ,30 minimum30Days Healthy  (33) 
Total and 18+ age group QoL estimates represent the weighted average of the age/sex 
group estimates, where the weights represent the relative share of persons with diabetes 
accounted for by each group. 
2.3.3.2 QALYs  
We used the integrated quality-survival product method to calculate QALYs. The method 
involves separate estimation of the survival function and the utility score. The population-
based QALY model was obtained by using the quality-adjusted survival curve (QAS). QAS is 
formed by plotting against time t, the product of the mean QoL score of the population alive 
at time t and the probability of surviving at time t. In our case, we considered k discrete 
time points (annual intervals from birth to age 100) to estimate the expected quality-
adjusted survival time and hence QALYs (Billingham et al., 1999): 
 
( ) ( ) ( )ii
k
i
iiii tt
SSQQ
QAS −
++
= +=
++∑ 11 11 22  (34) 
where Qi is the mean QoL at time ti, and Si is an estimate of the survival probability at time ti. Survival probabilities are estimated via life tables (i.e., ex = Tx/lx as described Section 
2.3.2) and differ by age, sex, and diabetes status. We used published national-level life 
expectancy for our QALY and YLL calculations so as not to confound state-level effects in life 
expectancy with diabetes prevalence by state. Average QALYs lost due to diabetes are 
averaged across each age in the age group. Total and 18+ age group estimates represent 
the weighted average of the age/sex group estimates, where the weights represent the 
relative share of persons with diabetes accounted for by each group. 
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Appendix A: 
Estimating Mortality, YLL, and QALYs 
Table A-1 shows the nine states with unreliable data on diabetes prevalence in the 
Behavioral Risk Factor Surveillance System (BRFSS) for the 18 to 44 age group. We defined 
reliable data as data where the number of respondents is greater than 50 and the relative 
standard error (RSE) of the weighted mean is less than 30% (Klein et al., 2002). We 
calculated the RSE using the following formula: 
 [ ]mean
meanoferrorStandard*100% =RSE  
For these states, prevalence across sexes was combined to obtain reliable estimates. For 
each state except Alaska and Wisconsin, the RSE was less than 30% for females but higher 
than 30% for males. 
Table A-1. Unreliable Values of Diabetes Prevalence Age 18 to 44 by State 
 Female Male 
State N RSE (%) N RSE (%) 
Alaska 888 33.8 841 31.0 
Arizona 581 26.4 493 37.6 
Delaware 774 20.9 612 32.7 
District Of Columbia 730 24.9 553 40.7 
Idaho 911 22.3 683 30.4 
Nevada 849 28.1 689 38.5 
New Hampshire 871 24.2 679 31.4 
Vermont 870 26.2 709 36.0 
Wisconsin 957 31.4 863 38.4 
Note: The number of diabetes diagnosis (N) was aggregated across the sexes because male 
prevalence in the state/age group were unreliable. 
Table A-2 shows all cases (48 out of 780) where CVD deaths + diabetes underlying cause + 
kidney deaths < all-cause deaths. Diabetes as the underlying cause and the number of 
deaths from kidney disease among individuals with diabetes are population-based counts. 
The number of deaths attributable to diabetes (all-cause deaths) and the number of 
cardiovascular disease (CVD) deaths attributable to diabetes are estimated obtained using 
the attributable fraction approach. Because we also independently estimated all-cause 
deaths and the deaths from the three specific causes, using different data sources, there is 
no guarantee that the cause-specific estimates will be less than the all-cause deaths 
attributable to diabetes. 
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Table A-2. Cases Where Cardiovascular Disease Deaths + Diabetes Underlying 
Cause + Kidney Deaths < All-Cause Deaths 
State Age Sex All Cause CVD UCD Kidney 
Alabama 15–44 F 64 56 27 12 
Arizona 15–44 F 34 14 41 15 
Arkansas 15–44 F 26 25 17 4 
California 15–44 F 177 108 97 48 
Colorado 15–44 F 18 9 15 7 
Connecticut 15–44 F 9 8 0 2 
Delaware 15–44 F 6 6 0 2 
District of Columbia 15–44 F 2 2 0 1 
Florida 15–44 F 99 63 65 36 
Georgia 15–44 F 81 70 36 37 
Hawaii 15–44 F 4 4 0 5 
Hawaii 75+ M 77 12 67 20 
Illinois 15–44 F 58 41 55 26 
Indiana 15–44 F 34 25 21 12 
Iowa 15–44 F 13 8 12 3 
Kentucky 15–44 F 42 33 23 10 
Louisiana 15–44 F 46 33 30 20 
Maine 15–44 F 5 4 0 2 
Maryland 15–44 F 40 32 21 9 
Massachusetts 15–44 F 22 9 12 6 
Michigan 15–44 F 60 44 34 22 
Minnesota 15–44 O 58 8 38 13 
Minnesota 15–44 F 12 8 15 6 
Mississippi 15–44 F 44 31 25 20 
Missouri 15–44 F 43 36 20 7 
Nebraska 15–44 F 6 5 0 2 
Nevada 15–44 F 15 12 13 1 
New Jersey 15–44 F 25 19 20 12 
New Mexico 75+ O 482 122 309 58 
New Mexico 75+ M 172 24 128 29 
(continued) 
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Table A-2. Cases Where Cardiovascular Disease Deaths + Diabetes Underlying 
Cause + Kidney Deaths < All-Cause Deaths (continued) 
State Age Sex All Cause CVD UCD Kidney 
New York 15–44 F 86 64 57 20 
North Carolina 15–44 F 71 52 45 18 
North Dakota 75+ F 114 38 68 14 
Ohio 15–44 F 59 53 47 28 
Oklahoma 15–44 F 38 29 24 12 
Oregon 15–44 F 15 6 15 4 
Pennsylvania 15–44 F 65 42 33 23 
Rhode Island 15–44 F 3 2 0 1 
South Carolina 15–44 F 40 38 12 17 
Tennessee 15–44 F 65 45 43 15 
Texas 15–44 F 138 97 95 75 
United States 15–44 F 1741 1231 1054 597 
Utah 15–44 F 10 3 14 6 
Vermont 75+ M 59 8 41 11 
Virginia 15–44 F 41 29 28 9 
Washington 15–44 F 26 15 26 12 
West Virginia 15–44 F 20 14 0 9 
Wisconsin 15–44 F 16 10 16 8 
Notes: CVD = cardiovascular disease, F = female, M = male, O = overall (both males and females), 
UCD = Diabetes as the underlying cause. UCD and Kidney (death) represent population-based 
averages. 
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Table A-3. Diabetes Prevalence at the National Level Used in the Computation of 
Years of Life Lost 
Sex Age Group 
Diabetes Prevalence 
(BRFSS 2013) RSE 
Male Age 18–24 1.0% 15.01 
Male Age 25–29 1.7% 17.83 
Male Age 30–34 2.1% 10.86 
Male Age 35–39 3.4% 8.39 
Male Age 40–44 5.9% 6.43 
Male Age 45–49 9.5% 5.03 
Male Age 50–54 13.3% 3.95 
Male Age 55–59 16.3% 3.43 
Male Age 60–64 19.7% 3.08 
Male Age 65–69 24.4% 2.65 
Male Age 70–74 25.1% 2.82 
Male Age 75–79 26.5% 3.89 
Male Age 80+ 21.7% 3.56 
Female Age 18–24 1.4% 14.84 
Female Age 25–29 1.6% 11.49 
Female Age 30–34 2.9% 9.24 
Female Age 35–39 4.1% 6.92 
Female Age 40–44 6.4% 5.82 
Female Age 45–49 8.9% 4.49 
Female Age 50–54 10.5% 3.94 
Female Age 55–59 15.0% 3.39 
Female Age 60–64 17.4% 2.81 
Female Age 65–69 20.6% 2.92 
Female Age 70–74 21.4% 2.64 
Female Age 75–79 21.8% 3.30 
Female Age 80+ 18.6% 2.98 
Note: RSE = relative standard error.  
Source: 2013 Behavioral Risk Factor Surveillance System (BRFSS). 
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Table A-4. Estimated EQ-5D Index from the Number of Healthy Days by Age 
Category 
Healthy 
Days 
EQ-5D 
18–24 Years 25–44 Years 45–64 Years 65–74 Years 75+ Years 
30 0.999 0.998 0.968 0.905 0.883 
29 0.998 0.995 0.834 0.823 0.811 
28 0.997 0.949 0.827 0.817 0.806 
27 0.994 0.842 0.823 0.809 0.795 
26 0.992 0.833 0.818 0.802 0.782 
25 0.914 0.827 0.809 0.796 0.778 
24 0.843 0.824 0.803 0.784 0.776 
23 0.839 0.821 0.800 0.779 0.773 
22 0.832 0.816 0.797 0.776 0.770 
21 0.829 0.811 0.795 0.776 0.769 
20 0.826 0.804 0.787 0.773 0.764 
19 0.824 0.801 0.778 0.770 0.758 
18 0.823 0.800 0.777 0.769 0.756 
17 0.821 0.799 0.776 0.768 0.753 
16 0.817 0.798 0.773 0.765 0.716 
15 0.805 0.793 0.767 0.740 0.708 
14 0.800 0.781 0.761 0.711 0.706 
13 0.799 0.776 0.759 0.711 0.706 
12 0.797 0.773 0.757 0.710 0.705 
11 0.797 0.771 0.755 0.710 0.705 
10 0.794 0.767 0.717 0.708 0.704 
9 0.789 0.763 0.709 0.707 0.702 
8 0.779 0.76 0.708 0.706 0.701 
7 0.773 0.758 0.708 0.706 0.701 
6 0.771 0.754 0.707 0.706 0.700 
5 0.768 0.716 0.706 0.705 0.699 
4 0.766 0.710 0.705 0.705 0.695 
3 0.765 0.709 0.705 0.705 0.694 
2 0.763 0.708 0.704 0.704 0.692 
1 0.760 0.706 0.704 0.703 0.689 
0 0.528 0.479 0.464 0.453 0.441 
Source: Table 2, Jia and Lubetkin (2008). EQ-5D = EuroQol five dimensions questionnaire. The EQ-5D 
is a standardized instrument for measuring generic health status. 
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